CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104)

BACKGROUND: Bevacizumab treatment at 2.5–5 mg/kg/week is associated with hearing improvement and tumor shrinkage in about 40% of patients with neurofibromatosis 2 (NF2) and progressive vestibular schwannomas (VS). Treatment-emergent hypertension and proteinuria are common with prolonged treatment, a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Plotkin, Scott, Tonsgard, James, Ullrich, Nicole, Allen, Jeffrey, Blakeley, Jaishri, Dhall, Girish, Campian, Jian, Clapp, Wade, Fisher, Michael, Cutter, Gary, Korf, Bruce, Packer, Roger, Thomas, Coretta, Edwards, Lloyd, Karajannis, Matthias
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Clinical Trials: Non-Immunologic
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650468/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.177
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы